| Patent Number |
Title Of Patent |
Date Issued |
| 6632438 |
Recombinant poxvirus cytomegalovirus, compositions, and uses |
October 14, 2003 |
| Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can b |
| 6596279 |
Immunodeficiency recombinant poxvirus |
July 22, 2003 |
| Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The |
| 6537594 |
Vaccina virus comprising cytokine and/or tumor associated antigen genes |
March 25, 2003 |
| Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on |
| 6267965 |
Recombinant poxvirus--cytomegalovirus compositions and uses |
July 31, 2001 |
| Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can b |
| 6265189 |
Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen |
July 24, 2001 |
| Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on |
| 6130066 |
Vectors having enhanced expression and methods of making and uses thereof |
October 10, 2000 |
| Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid mo |
| 6017542 |
Nucleotide and amino acid sequences of canine herpesvirus GD and uses therefor |
January 25, 2000 |
| Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed and claimed. The genes are useful as DNA probes or, for preparing PC |
| 6004777 |
Vectors having enhanced expression, and methods of making and uses thereof |
December 21, 1999 |
| Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid mo |
| 5990091 |
Vectors having enhanced expression, and methods of making and uses thereof |
November 23, 1999 |
| Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid mo |
| 5989561 |
Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
November 23, 1999 |
| Attenuated recombinant viruses containing DNA encoding a calicivirus antigen such as a RHDV antigen, e.g., a capsid gene, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are di |
| 5891442 |
Infectious bursal disease virus recombination poxvirus vaccine |
April 6, 1999 |
| What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. |
| 5863542 |
Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
January 26, 1999 |
| Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The |
| 5858373 |
Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for |
January 12, 1999 |
| Attenuated recombinant viruses containing DNA encoding FIPV antigen(s) compositions thereof, as well as methods for making and using the compositions, expression products therefrom, and antibodies generated, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC rec |
| 5843456 |
Alvac poxvirus-rabies compositions and combination compositions and uses |
December 1, 1998 |
| Attenuated recombinant viruses containing DNA encoding a rabies virus antigen in a "cocktail" or combination or multivalent compositions well as methods for making and using the compositions, expression products therefrom, and antibodies generated, are disclosed and claimed. The reco |
| 5833975 |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
November 10, 1998 |
| Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA ca |
| 5766599 |
Trova fowl pox virus recombinants comprising heterologous inserts |
June 16, 1998 |
| What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one |
| 5766598 |
Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segme |
June 16, 1998 |
| This invention is directed toward recombinant attenuated canarypox virus expression vectors containing exogenous DNA segments encoding lentiviral gene products. A parental canarypox virus (Rentschler strain) was obtained and attenuated through more than 200 serial passages on chick embry |
| 5766597 |
Malaria recombinant poxviruses |
June 16, 1998 |
| What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also descri |
| 5762938 |
Modified recombinant vaccinia virus and expression vectors thereof |
June 9, 1998 |
| What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one |
| 5759841 |
Immunological composition of measles virus utilizing recombinant poxvirus |
June 2, 1998 |
| What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is ex |
| 5759553 |
Marek's disease virus recombinant poxvirus vaccine |
June 2, 1998 |
| What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the |
| 5759552 |
Marek's disease virus recombinant poxvirus vaccine |
June 2, 1998 |
| What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the |
| 5756103 |
Alvac canarypox virus recombinants comprising heterlogous inserts |
May 26, 1998 |
| What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one |
| 5756102 |
Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the re |
May 26, 1998 |
| Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine |
| 5744141 |
Flavivirus recombinant poxvirus immunological composition |
April 28, 1998 |
| What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an e |
| 5688920 |
Nucleotide and amino acid sequences for canine herpesvirus GB, GC and GD and uses therefor |
November 18, 1997 |
| Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed and claimed. The genes are useful as DNA probes or, for preparing PC |
| 5658572 |
Infectious bursal disease virus recombinant poxvirus vaccine |
August 19, 1997 |
| What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. |
| 5641490 |
Infectious bursal disease virus recombinant poxvirus vaccine |
June 24, 1997 |
| What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. |
| 5529780 |
Nucleotide and amino acid sequences of canine herpesvirus gB and gC |
June 25, 1996 |
| Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed. The nucleotides can be expressed in any suitable vector system, all |
| 5514375 |
Flavivirus recombinant poxvirus vaccine |
May 7, 1996 |
| What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an e |
| 5503834 |
Measles virus recombinant poxvirus vaccine |
April 2, 1996 |
| What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is ex |
| 5494807 |
NYVAC vaccinia virus recombinants comprising heterologous inserts |
February 27, 1996 |
| What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one |
| 5378457 |
Interferon sensitive recombinant poxvirus vaccine |
January 3, 1995 |
| What is described is a recombinant poxvirus, such as vaccinia virus, having enhanced sensitivity to interferon. In one embodiment, the recombinant poxvirus has an open reading frame conferring resistance to interferon deleted therefrom. In another embodiment, the recombinant poxvirus is |
| 5364773 |
Genetically engineered vaccine strain |
November 15, 1994 |
| What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one |
